Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion

Eye

Volumn 24, Issue 8, 2010, Pages 1414-

  Hu, Y J ^a  

^a Shantou University Medical College   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

CATARACT; CENTRAL RETINA VEIN OCCLUSION; DRUG EFFICACY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LETTER; RETINA MACULA EDEMA; TONOMETER; VISUAL ACUITY;

EID: 77955630305     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2010.35     Document Type: Letter

References (3)

1. Wu WC, Cheng KC, Wu HJ. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye (London) 2009; 23(12): 2215-2222.
2. Cheng KC, Wu WC, Lin CJ. Intravitreal triamcinolone acetonide for patients with macular oedema due to central retinal vein occlusion in Taiwan. Eye (London) 2009; 23(4): 849-857.
3. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M et al. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127(9): 1101-1114. Erratum in: Arch Ophthalmol 2009; 127(12): 1648.